First neuro product approved in Forfait Innovation 


Evasc Neurovascular has announced its successful application to France’s Ministry of Health (Haute Autorité de la Santé, HAS) Forfait Innovation (FI) programme for the eCLIPs device.

According to a company press release, the Forfait Innovation program grants clinical trial funding to evaluate CE marked devices that are deemed to be “truly innovative” and offer significant clinical benefit, filling an unmet medical need. 

Evasc Neurovascular claims the eCLIPs device is the first neuro device that has gained  Forfait Innovation approval and funding. The funded amount of €2.76 million covers hospital costs of a 119 patient trial against optimal performance criteria.

Donald Ricci, CEO of Evasc Neurovascular, comments: “We are pleased to have confirmation by an influential and independent third party, the French Ministry of Health, that eCLIPs represents an innovation in the treatment of intracranial bifurcation aneurysms, a consistent message in our presentations, publications and discussions with neurointerventionalists over the past few years.”


Please enter your comment!
Please enter your name here